...
首页> 外文期刊>Journal of Thoracic Disease >Endovascular treatment of complex diseases of the thoracic aorta—10 years single centre experience
【24h】

Endovascular treatment of complex diseases of the thoracic aorta—10 years single centre experience

机译:胸主动脉复杂疾病的血管内治疗-10年单中心经验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Introduction of invasive endovascular techniques constituted a real a breakthrough in the treatment of aortic aneurysm dissection and rupture. We assessed the effectiveness and safety of thoracic endovascular aortic repair (TEVAR) in patients with thoracic aortic pathologies. Methods: Between 2007 and 2017, 118 patients with thoracic aortic pathology underwent TEVAR. Among them, 20 (16.9%) patients required hybrid procedures. Stent grafts indication were thoracic aortic aneurysm in 46 (39.0%) patients, type B dissection in 68 (57.6%) patients and other indications in 4 (3.3%). Procedural success rate, in-hospital and late mortality and morbidity were evaluated. Results: The patients were followed-up for a mean of 55 months (range, 6-118 months). The technical success rate was 96%. Five patients died during the first 30 days after procedure (mortality 4.2%), four due to ischemic stroke followed by multi-organ failure and another one hemodynamically significant type I endoleak. Most of them were noted in the first years of our study. Five others died during post-discharged period. Four patients developed neurological complications, including stroke (n=2; 1.7%) and paraparesis (n=2; 1.7%). There were 6 (5.1%) primary (5 type I and 1 type II) and 3 (2.5%) secondary endoleaks (1 type I and 2 type III). Secondary interventions were required in 8 subjects. There was one case of stent collapse and two retrograde aortic dissection. Conclusions: Treatment of descending aortic diseases by using stent graft implantation has become the method of choice, decreasing the risk of open surgery, especially in patients with severe clinical state and comorbidities. However, effectiveness and safety may be achieved by experience team.
机译:背景:侵入性血管内技术的引入,在主动脉瘤解剖和破裂的治疗方面真正实现了突破。我们评估了胸主动脉病变患者的胸腔内血管主动脉修复(TEVAR)的有效性和安全性。方法:在2007年至2017年之间,对118例胸主动脉病变患者进行了TEVAR。其中,有20名(16.9%)患者需要混合手术。支架移植指征为胸主动脉瘤46例(39.0%),B型夹层术68例(57.6%),其他指征4例(3.3%)。评估了手术成功率,院内和晚期死亡率及发病率。结果:对患者平均随访55个月(范围6-118个月)。技术成功率为96%。在手术后的前30天内有5例患者死亡(死亡率为4.2%),其中4例由于缺血性中风继之以多器官衰竭而死亡,另外1例因血液动力学显着性I型内漏。在我们的研究的头几年中,大多数被记录下来。出院后有五人死亡。四名患者出现神经系统并发症,包括中风(n = 2; 1.7%)和轻瘫(n = 2; 1.7%)。有6个(5.1%)原发性内漏(5个I型和1个II型)和3个(2.5%)次生内渗漏(1个I型和2个III型)。 8名受试者需要二次干预。有1例支架塌陷和2例逆行主动脉夹层。结论:通过支架植入术治疗降主动脉疾病已成为一种选择的方法,降低了开放手术的风险,特别是在患有严重临床疾病和合并症的患者中。但是,经验团队可能会实现有效性和安全性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号